EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Neoantigen-directed therapeutics in the clinic: where are we?

Lien Lybaert, Kris Thielemans, Steven A Feldman, Sjoerd H van der Burg, Cedric Bogaert, Patrick A Ott

Trends in Cancer · 2023

DOI: 10.1016/j.trecan.2023.02.004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2023. Verfasst von Lien Lybaert und 5 weiteren Autor:innen. Beteiligte Einrichtung: myNEO NV, 9000 Ghent, Belgium. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the past decade, immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T cell therapy have brought immunotherapy to the forefront of cancer treatment; however, only subsets of patients benefit from current approaches. Neoantigen-driven therapeutics specifically redirect the immune system of the patient to enable or reinduce its ability to recognize and eliminate cancer cells. The tumor specificity of this strategy spares healthy and normal cells from being attacked. Consistent with this concept, initial clinical trials have demonstrated the feasibility, safety, and immunogenicity of neoantigen-directed personalized vaccines. We review neoantigen-driven therapy strategies as well as their promise and clinical successes to date.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, NeoplasmNeoplasmsHumansImmunotherapyImmunotherapy, AdoptiveImmune System

Stichwörter der Autor:innen

T cellT cell receptorcell therapyneoantigenpersonalizedvaccine

Substanzen

Antigens, Neoplasm

Autor:innen und Institutionen

  • myNEO NV, 9000 Ghent, Belgium.
  • Center for Cancer Cell Therapy, Stanford University School of Medicine, Stanford, CA, USA.
  • Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.
  • myNEO NV, 9000 Ghent, Belgium. Electronic address: cedric@myneo.me.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: Patrick_ott@dfci.harvard.edu.

Förderung

  • NCI NIH HHS

Zitieren

APA

Lybaert, L., Thielemans, K., Feldman, S. A., van der Burg, S. H., Bogaert, C., & Ott, P. A. (2023). Neoantigen-directed therapeutics in the clinic: where are we?. Trends in Cancer. https://doi.org/10.1016/j.trecan.2023.02.004

Vancouver

Lybaert L, Thielemans K, Feldman SA, van der Burg SH, Bogaert C, Ott PA. Neoantigen-directed therapeutics in the clinic: where are we?. Trends in Cancer. 2023. doi:10.1016/j.trecan.2023.02.004

BibTeX
@article{Lybaert2023,
  author = {Lybaert, Lien and Thielemans, Kris and Feldman, Steven A and van der Burg, Sjoerd H and Bogaert, Cedric and Ott, Patrick A},
  title = {Neoantigen-directed therapeutics in the clinic: where are we?},
  journal = {Trends in Cancer},
  year = {2023},
  doi = {10.1016/j.trecan.2023.02.004}
}
Kostenlos starten →